Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2015-03-04 Regulatory Filings
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, including details about the collaboration, payments, and related party interests. There are no financial statements or detailed financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy statement, earnings release, or other specific report type. The document is a regulatory announcement of a significant corporate event, fitting the category of Regulatory Filings (RNS). The document length is 3555 characters, which is relatively short and consistent with an 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-03-04 English
SC 13G/A
Major Shareholding Notification
2015-02-17 English
SC 13G/A
Major Shareholding Notification
2015-02-17 English
Major Shareholding Notification 2015
Major Shareholding Notification
2015-02-17 English
Regulatory Filings 2015
Regulatory Filings
2015-01-22 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically discusses the company's intention to use social media channels for material information dissemination, which is an 'Other Events' disclosure under Item 8.01. There are no financial statements, earnings data, or detailed reports included. The document is relatively short (2821 characters) and serves as a notification rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2015-01-21 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.